Hyperthermia malignant

Malignant hyperthermia (MH) is an autosomal-dominant pharmacogenetic disorder that is triggered by exposure to inhalation of general anesthetics, such as halothane. In susceptible individuals, these drugs can induce tachycardia, a greatly increased body metabolism, muscle contracture and an elevated body temperature (above 40°C) with a rapid rate of increase. Many cases of MH are linked to a gene for type 1 ryanodine receptor (RyRl). 

Robinson R, Carpenter D, Shaw MA et al (2006) Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27 977-989... 

Transmission is autosomal dominant, and the relevant gene has been mapped to the same locus on chromosome 19q as that associated with susceptibility to malignant hyperthermia (pages 318-319). It is not established that the conditions are allelic. Almost all patients with CCD whose muscle has been tested in vitro for... 

Malignant hyperthermia may occur outside the operating room. Gronert has described a patient who had episodic fever and a positive muscle biopsy for MH. MH may occur in the postoperative recovery room or even on return to the ward. 

Table 1. Associated Musculoskeletal Disorders in Patients Susceptible to Malignant Hyperthermia...

Table 2. Conditions That May Initially Resemble Malignant Hyperthermia...

Denboroug, M.A., Phil, D. (1985). Current concepts of the etiology and treatment of malignant hyperthermia susceptible patients (letter). Anesthesiology 62,99. 

Experience in the prospective management of either children. J. Ped. Surg. 24, 163-166. Gronert, G.A. (1980), Malignant hyperthermia. Anesthesiology 53,395-413. 

Huckell, F.V. (1986). Cardiac manifestations of malignant hyperthermia susceptibility. Circulation 58,... 

Johnson, C., Edleman, K. (1993). Malignant hyperthermia A review. J. Perinatology 12,61-71. Kalow, W., Britt, B.A., Chan, F. Y. (1992). Epidemiology and inheritance of malignant hyperthermia. Inti. Anesth. Clinic 17, 119-140. 

Kaplan, R.F., Kellner, K.R. (1985). More on malignant hyperthermia during delivery. Am J. Obst. Gynec. 152, 5608. 

Larew, R.E.B. (1989). Malignant hyperthermia, quick recognition to avoid death. Post Grad Med. 85, 117-118. 

MacLennan, D.H., Duff, C., Zorgato, F., et al. (1990). Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343, 559-561. 

Merz, B. (1986). Malignant hyperthermia Nightmare for anesthesiologists and patients. Medical News 255, 709-715. 

Moore, D.C. (1986). Ester or amide local anesthetics in malignant hyperthermia— Who knows Anesthesiology 54, 294-296. 

Ording, H. (1985). Incidence of malignant hyperthermia in Denmark. Anesth. Analg. 64,700-704. 

Fill, M., Stefani, E., Nelson, T.E (1991). Abnormal sarcoplasmic reticulum Ca release channels in malignant hyperthermia skeletal muscle. Biophys. J. 59, 1085-1090. 

Harrison, G.G. (1979). Porcine malignant hyperthermia. Inti. Anesthesiol. Clin. 17, 25-62. 

Mackenzie, A.E., Allen, G., Lahey, D., Crossen, M.L., Nolan, K., Mettler, G., Worton, R.G., MacLen-nan, D.H., Korneluk, R. (1991). A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia. Anesthesiology 75,4-8. 

Otsu, K., Phillips, M.S., Khanna, V.K., de Leon, S., MacLennan, D.H. (1992). Refinement of diagnostic assays for a probable causal mutation for porcine and human malignant hyperthermia. Genomics 13, 8325-837. 

Malignant hyperthermia Myotonias and masseter spasm Hyperkaliemia... 

Mutations in the Gene Encoding the Ca + Release Channel Are One Cause of Human Malignant Hyperthermia... 

---